Skip to main content

Branded

  • Engaging patients: Health care’s new ‘holy grail’

    It has been called “the blockbuster drug of the century,” the holy grail of health care and the next great frontier in the search for a more responsive and cost-effective healthcare system. But is it a truly achievable goal, and will it really transform the way health care is delivered in the United States?

  • FDA wants more clinical trial data before approving Forest, Gedeon Richter psychiatric drug

    NEW YORK — The Food and Drug Administration has declined to approve an experimental drug for schizophrenia and bipolar disorder developed by Forest Labs and Gedeon Richter, a Hungarian drug company, the two said Thursday.

    The companies said the FDA issued a complete-response letter for cariprazine. The agency issues a complete-response letter when it has finished reviewing an application but issues remain that preclude final approval. In the letter, the FDA acknowledged the drug's efficacy, but wanted more clinical trial data.

  • The push for pharmacist provider status

    Pharmacists traditionally have been one of the most underutilized members of the healthcare team, possibly because they hadn’t been officially recognized as part of that team. That, however, is about to change.

  • Oral drugs gain on injectables in multiple sclerosis market, study finds

    BURLINGTON, Mass. — Use of injectable drugs for multiple sclerosis declined during the 12-month period that ended on June 30 as orally administered drugs for the condition became more popular, according to a new report.

  • Spending on drugs in the United States expected to grow again next year after falling

    NEW YORK — Global spending on drugs will pass the $1 trillion mark next year, according to a new study by the IMS Institute for Healthcare Informatics, a division of healthcare market analysis firm IMS Health.

  • Upsher-Smith to present phase-3 trial data of experimental epilepsy drug

    MAPLE GROVE, Minn. – Drug maker Upsher-Smith Labs will present data from a late-stage trial of a drug for treating epilepsy, the company said Monday.

  • Senate passes Drug Quality and Security Act

    NEW YORK — A bill that would implement federal tracking and tracing of drugs and strengthen federal regulations on pharmacy compounding has passed in the Senate and will go to President Barack Obama for his signature.

  • FDA approves one-week antifungal drug made by Valeant

    LAVAL, Quebec — The Food and Drug Administration has approved a new drug for fungal infections of the skin made by Valeant Pharmaceuticals International, the drug maker said Friday.

    The company announced the FDA approval of Luzu (luliconazole) cream in the 1% strength for treatment of athlete's foot, jock itch and ringworm in adults.

X
This ad will auto-close in 10 seconds